Irina Viktorovna Kondakova

Irina Viktorovna Kondakova

Auto-generated profile, based on publicly available information

Irina Viktorovna Kondakova

Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in Clinical and experimental thyroidology
Verified
Journal Article
Open access
PDF file
LSLuidmila Spirina
Luidmila Spirina
SCSvetlana Y. Chizhevskaya
Svetlana Y. Chizhevskaya
IKIrina V. Kondakova
Irina V. Kondakova
NTNataliya V. Tarasenko
Nataliya V. Tarasenko
ЧЮЧижевская Светлана Юрьевна
Чижевская Светлана Юрьевна
Autophagy is an important intracellular process that supports cell death and survival. Oncogenesis is associated with a change in the AKT/mTOR signaling pathway status. At the same time, the existence of protective autophagy, as one of the mechanisms of disease progression and the formation of resistance to treatment, has been proven. The review describes the significant mechanisms of the autophagy development, its association with AKT/mTOR signaling pathway. A molecule mTOR in TORC1 complex is associated with the oncogenesis, it provides the proliferation of transformed cells, apoptosis inhibition, and to the development of autophagy. The participation of this phenomenon at all stages of carcinogenesis, influencing on the main signal kinases: AKT, mTOR, is noted. It is shown that in most cases this mechanism is responsible for the progression of the disease and the development of resistance to treatment. The development of thyroid cancer associated with the BRAF mutation and with the activation of the RET oncoprotein, as well as with the formation of radio-resistant forms of the disease is associated with molecular peculiarities of autophagy. Given the inconsistency of this phenomenon regarding their influence on the processes of oncogenesis, its role in the development of thyroid cancer is still unknown.

11 September 2018 in Problems of Endocrinology
Verified
Journal Article
Open access
LSLiudmila V. Spirina
Liudmila V. Spirina
SCSvetlana Y. Chizhevskaya
Svetlana Y. Chizhevskaya
IKIrina V. Kondakova
Irina V. Kondakova
Background: The molecular mechanism of thyroid cancer development is associated with changes in expression of transcription factors and growth factors accompanied by modified level of the AKT/m-TOR components. Aims. The aim of study was to determine NF-κB p65, NF-κB p50, HIF-1α, HIF-2α, VEGF, CAIX, VEGFR2 expression and mRNA level of the AKT/m-TOR signaling pathway components in papillary thyroid cancer compared to those in benign lesions. Material and methods: Forty patients aged 33—66 years with T1-4N0-2M0 papillary thyroid cancer (7 males and 33 females) were enrolled in the study. The mean age was 52.0±2.6 years. The comparison group included patients with benign lesions of thyroid tissue (4 males and 18 females) aged 38—66 years (mean age, 53.0±4.4 years). Expression levels of NF-κB p65, NF-κB p50, HIF-1α, HIF-2α, VEGF, CAIX, VEGFR2, and the AKT/m-TOR signaling pathway components were determined by RT-PCR using specific primers. Results: Increased expression of transcription factors NF-κB and HIF-2α was found in papillary thyroid cancer. The levels of AKT and PTEN mRNA were elevated in transformed tissues. c-Raf expression was reduced 2.1-fold in cancer compared to that in thyroid tissues with benign lesions. Multiple positive correlations were revealed between transcription and growth factors and the AKT/m-TOR signaling pathway components in cancer. An association between PTEN expression and the NF-κB mRNA level was revealed, being a sign of deregulation in the signaling cascade in cancer tissues. Conclusions: Overexpression of NF-κB, HIF-2α, AKT, PTEN and reduction of c-Raf expression is typical of thyroid papillary cancer.

15 December 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
EZE. A. Zambalova
E. A. Zambalova
MPMarina Patysheva
Marina Patysheva
ADA. A. Dimcha
A. A. Dimcha
STSvetlana Tamkovich
Svetlana Tamkovich
AGA. E. Grigor’eVa
A. E. Grigor’eVa
NYNatalia v Yunusova
Natalia v Yunusova
The objective is to evaluate the level of ADAM10 and ADAM17 (a disintegrin and metalloproteinase) proteases, as well as 20S-proteasomes in blood plasma exosomes of patients with colorectal cancer.Materials and methods. The study included 60 patients with colorectal cancer (T2–4N0–2M0–1) and 10 control patients. The material for the study was EDTA blood plasma. Exosomes of blood plasma were isolated by ultrafiltration with ultracentrifugation. The level of tetraspanin-associated (ADAM10 and ADAM17) and tetraspanin-non-associated (20S-proteasome) proteases was evaluated by flow cytometry and Western blotting.Results. A twice negative subpopulation (ADAM10–/ADAM17–) predominated in blood plasma exosomes of colorectal cancer patients and control patients. The level of ADAM10+/ADAM17– exosomes was significantly higher in the exosomes of the plasma of control patients. There were no significant differences between the ADAM10/ADAM17 subpopulations and the 20S-proteasome level, depending on sex, age and tumor grade. A decrease in the ADAM10+/ADAM17– subpopulation was found in patients with metastatic colorectal cancer with hematogenous metastases compared with patients with T2–4N1–2M0 and 20S-proteasome compared to T2–4N0M0. A decrease in ADAM10–/ ADAM17+ exosomes and 20S-proteasomes level was found in exosomes of patients with colorectal cancer with a metabolic syndrome in comparison with patients without metabolic disorders.

15 January 2019 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
LSLuidmila Spirina
Luidmila Spirina
AGA. K. Gorbunov
A. K. Gorbunov
IKI. V. Kondakova
I. V. Kondakova
EUE. A. Usynin
E. A. Usynin
ESE. M. Slonimskaya
E. M. Slonimskaya
The expected effect of androgen-deprivation therapy is one of the important criteria when choosing therapy in patients with prostate cancer. No less significant factor is the time of its implementation. The study showed that high expression of androgen receptors (AR) in the tumor tissue against the background of low estrogen receptor α (ERα) expression is characteristic of patients in whom the effect of androgen-deprivation therapy was observed for 12 months. A set of parameters has been identified that makes it possible to predict the duration of response to androgen-deprivation therapy in patients with prostate cancer, which include the patient’s age, testosterone level, prostate specific antigen, expression level of AR, ERα. These data allow us to consider these parameters as additional informative markers, to predict not only the expected effect, but also its duration.

15 December 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
LSLuidmila Spirina
Luidmila Spirina
IKI. V. Kondakova
I. V. Kondakova
NTN. V. Tarasenko
N. V. Tarasenko
Тhe protein TRIM16 is involved in key intracellular processes, such as proliferation, cell differentiation and programmed death, including intrinsic and extrinsic apoptosis, autophagy-dependent cell death and immunogenic cell death. The TRIM16 protein acts the proteins TPD43, Gli-1, RARβ, Snail components and MAPK signaling pathway, cadherins, caspases and is also associated with the regulation of the immune system via direct and indirect mechanisms. The influence of TRIM16 protein on the pathogenesis of hormone-dependent tumors is well-known. Further study of the TRIM16 role in the development and progression of malignant neoplasms will form the basis for the development of new methods for predicting the course of the malignant process.

15 September 2019 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
NYNatalia v Yunusova
Natalia v Yunusova
EZE. A. Zambalova
E. A. Zambalova
MPMarina Patysheva
Marina Patysheva
ADA. A. Dimcha
A. A. Dimcha
OCO. V. Cheremisina
O. V. Cheremisina
IKI. V. Kondakova
I. V. Kondakova
The objective is to evaluate the contents of matrix metalloproteinases (MMP) MMP9, MMP2, as well as their inducer EMMPRIN in circulating exosomes of patients with colorectal cancer in relation with clinical and morphological parameters, as well as with the presence of metabolic syndrome to search for promising exosomal markers associated with invasion, metastasis and metabolic disorders.Materials and methods. The study included 40 patients with colorectal cancer (T2–4N0–2M0–1) and 10 control patients. Exosomes of blood plasma were isolated by ultrafiltration with ultracentrifugation. The level of MMP9, MMP2 and their inducer EMMPRIN in exosomes was evaluated by flow cytometry.Results and conclusion. The level of MMP9‑positive exosomes was significantly higher in patients with colorectal cancer compared with patients with colorectal polyps. The proportion of MMP9‑negative and triple positive MMP9 + / MMP2+ / EMMPRIN+ exosomes, on the contrary, was higher in patients with polyps compared with patients with colorectal cancer. Mixed subpopulation of MMP9+ / MMP2– / EMMPRIN-exosomes prevailed both in patients with colorectal cancer and in control patients. There were no significant differences in the subpopulations of MMP and EMMPRIN in the exosomes of colorectal cancer patients depending on the age, stage, grade and localization. Gender differences in the occurrence of a triple-positive exosome subpopulation in colorectal cancer patients have been revealed. No relationship was found between the expression of MMP and EMMPRIN in exosomes and the presence of the metabolic syndrome, anthropometric parameters, the level of total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol. However, the relationships between MMP9+ / MMP2– / EMMPRIN–, MMP9+ / MMP2– / EMMPRIN– and the level of triglycerides and glucose in blood serum were revealed. Further studies are needed to study the characteristics of exosomes associated with metabolic disorders and the possibility of their use as diagnostic, prognostic, or predictor biomarkers.